T0	Participants 116 148	patients with advanced melanoma.
T1	Participants 570 737	Treatment-naïve or previously treated patients with unresectable stage III/IV melanoma (n = 115) received open-label ipilimumab (10 mg/kg every 3 weeks for four doses)